Pfizer, a US drugmaker Wednesday sharply increased its 2021 projection for revenues tied to its COVID-19 vaccine forecasting generating US$33.5-billion in sales instead of US$26-billion predicted in May.
The company which has partnered with Germany’s BioNTech on the vaccine is estimating to deliver 2.1 billion doses.
Introducing the Pindula News Mobil App
Download from Google Play Store
Pfizer Chief Executive Albert Bourla said more than a billion doses of the vaccine have been delivered, saying “the speed and efficiency of our efforts with BioNTech to help vaccinate the world against COVID-19 have been unprecedented.”
Pfizer said the pre-tax profit margin on the COVID-19 vaccine sales was in the “high-20s” in terms of per cent, the same as the earlier forecast.
The drugmaker reported second-quarter profits of $5.6-billion, up 59 per cent from the year-ago period on a 92 per cent increase in revenues to $19 billion.
- Pfizer pushes for a third shot as Delta drives global outbreaks
- Pfizer/BioNTech To Produce COVID-19 Vaccine In South Africa
- COVID-19 Vaccine: 23 Die Within Days Of Receiving Pfizer
- COVID-19 Vaccines Do Not Harm Sperm Count – Study
- Local Health Expert Explains Norwegian COVID-19 Vaccine Deaths
Pfizer has launched clinical studies on a possible third dose of the COVID-19 vaccine as a booster shot. Bourla has said such boosters could amount to a “durable” revenue stream for the company.
US health officials have thus far not far backed a third shot for the broad population, but officials are studying the need for a third shot in immunocompromised people.